Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)

Bruce E. Johnson; Tae Min Kim; T. Jeroen N. Hiltermann; Fabrice Barlesi; Christian Grohe; Yasushi Goto; Orvar Gunnarsson; Tobias Overbeck; Noemi Reguart; Martin Wermke; Gilberto Castro; Enriqueta Felip; Alastair Greystoke; Benjamin J. Solomon; Noelia Nebot; Stephanie Deudon; Anne-Laure Louveau; Vanessa Q. Passos; Daniel S. W. Tan

doi:10.1158/1535-7163.TARG-19-C100

Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)

Bruce E. Johnson, Tae Min Kim, T. Jeroen N. Hiltermann, Fabrice Barlesi, Christian Grohe, Yasushi Goto, Orvar Gunnarsson, Tobias Overbeck, Noemi Reguart, Martin Wermke, Gilberto Castro, Enriqueta Felip, Alastair Greystoke, Benjamin J. Solomon, Noelia Nebot, Stephanie Deudon, Anne-Laure Louveau, Vanessa Q. Passos, Daniel S. W. Tan

Translational Immunology Groningen (TRIGR)

Onderzoeksoutput › Academic

Originele taal-2	English
Aantal pagina's	3
Tijdschrift	Molecular cancer therapeutics
Volume	18
Nummer van het tijdschrift	12
DOI's	https://doi.org/10.1158/1535-7163.TARG-19-C100
Status	Published - dec.-2019

Toegang tot document

10.1158/1535-7163.TARG-19-C100

Handle.net

Permanente koppeling

Citeer dit

Johnson, B. E., Kim, T. M., Hiltermann, T. J. N., Barlesi, F., Grohe, C., Goto, Y., Gunnarsson, O., Overbeck, T., Reguart, N., Wermke, M., Castro, G., Felip, E., Greystoke, A., Solomon, B. J., Nebot, N., Deudon, S., Louveau, A.-L., Passos, V. Q., & Tan, D. S. W. (2019). Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1). Molecular cancer therapeutics, 18(12). https://doi.org/10.1158/1535-7163.TARG-19-C100

Johnson, Bruce E. ; Kim, Tae Min ; Hiltermann, T. Jeroen N. et al. / Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1). In: Molecular cancer therapeutics. 2019 ; Vol. 18, Nr. 12.

@article{79698455c1d4458d928b4a810dd9c11c,

title = "Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)",

author = "Johnson, {Bruce E.} and Kim, {Tae Min} and Hiltermann, {T. Jeroen N.} and Fabrice Barlesi and Christian Grohe and Yasushi Goto and Orvar Gunnarsson and Tobias Overbeck and Noemi Reguart and Martin Wermke and Gilberto Castro and Enriqueta Felip and Alastair Greystoke and Solomon, {Benjamin J.} and Noelia Nebot and Stephanie Deudon and Anne-Laure Louveau and Passos, {Vanessa Q.} and Tan, {Daniel S. W.}",

year = "2019",

month = dec,

doi = "10.1158/1535-7163.TARG-19-C100",

language = "English",

volume = "18",

journal = "Molecular cancer therapeutics",

issn = "1535-7163",

publisher = "AMER ASSOC CANCER RESEARCH",

number = "12",

}

Johnson, BE, Kim, TM, Hiltermann, TJN, Barlesi, F, Grohe, C, Goto, Y, Gunnarsson, O, Overbeck, T, Reguart, N, Wermke, M, Castro, G, Felip, E, Greystoke, A, Solomon, BJ, Nebot, N, Deudon, S, Louveau, A-L, Passos, VQ & Tan, DSW 2019, 'Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)', Molecular cancer therapeutics, vol. 18, nr. 12. https://doi.org/10.1158/1535-7163.TARG-19-C100

Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1). / Johnson, Bruce E.; Kim, Tae Min; Hiltermann, T. Jeroen N. et al.
In: Molecular cancer therapeutics, Vol. 18, Nr. 12, 12.2019.

Onderzoeksoutput › Academic

TY - JOUR

T1 - Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)

AU - Johnson, Bruce E.

AU - Kim, Tae Min

AU - Hiltermann, T. Jeroen N.

AU - Barlesi, Fabrice

AU - Grohe, Christian

AU - Goto, Yasushi

AU - Gunnarsson, Orvar

AU - Overbeck, Tobias

AU - Reguart, Noemi

AU - Wermke, Martin

AU - Castro, Gilberto

AU - Felip, Enriqueta

AU - Greystoke, Alastair

AU - Solomon, Benjamin J.

AU - Nebot, Noelia

AU - Deudon, Stephanie

AU - Louveau, Anne-Laure

AU - Passos, Vanessa Q.

AU - Tan, Daniel S. W.

PY - 2019/12

Y1 - 2019/12

U2 - 10.1158/1535-7163.TARG-19-C100

DO - 10.1158/1535-7163.TARG-19-C100

M3 - Meeting Abstract

SN - 1535-7163

VL - 18

JO - Molecular cancer therapeutics

JF - Molecular cancer therapeutics

IS - 12

ER -

Johnson BE, Kim TM, Hiltermann TJN, Barlesi F, Grohe C, Goto Y et al. Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1). Molecular cancer therapeutics. 2019 dec.;18(12). doi: 10.1158/1535-7163.TARG-19-C100